Sep 17, 2024 · Alzheimer's disease biomarkers are positive in around 50% of patients with dementia with Lewy bodies and are associated with worse cognition.
Missing: novel | Show results with:novel
Sep 9, 2024 · Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology, 68 (2007), pp. 666-669, 10.1212/01.wnl ...
Sep 14, 2024 · We show that the presence of LB pathology exacerbates global cognitive decline in symptomatic AD and is associated with more pronounced hypometabolism, ...
Sep 12, 2024 · In this cross-sectional study, we showed the potential of a diagnostic biomarker-based algorithm for the discrimination of AD and 4RTs. We demonstrated that a ...
Sep 17, 2024 · Pinpointing novel risk loci for Lewy body dementia and the shared genetic etiology with Alzheimer's ... amyloid β, and tau accumulation in Lewy body dementia. Ann ...
Sep 7, 2024 · Evidence of Aβ and tau pathologies can be clinically assessed for the diagnosis of AD using cerebrospinal fluid (CSF; i.e., low Aβ42/40 ratio and high ...
Sep 6, 2024 · Evaluation of the EUROIMMUN automated chemiluminescence immunoassays for measurement of four core biomarkers for Alzheimer's disease in cerebrospinal fluid.
Sep 23, 2024 · Alzheimer's Disease (AD) is the most common type, representing 60-70% of dementia cases, followed by Frontotemporal Dementia (FTD) and Lewy Body Dementia (DLB).
Sep 24, 2024 · CSF phosphorylated tau concentrations specifically predicted amyloid deposition in healthy elderly and a subsequent decline in cognitive status. Results ...
Sep 17, 2024 · CSF and plasma pTau181 showed correlation in all phenotypes except in SCD and other dementias. Age significantly influenced the biomarker's performance. The ...